Symlin

(pramlintide)

ApprovedPeptide

AstraZeneca

Symlin is one of 115 small molecule programs targeting Schizophrenia. It is currently in Approved.

Indications

Total Trials

Active Trials

114

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

SchizophreniaActive, not recruiting

Type 1 DiabetesWithdrawn

HypoglycemiaCompleted

HyperglycemiaCompleted

SchizophreniaApproved

Active, not recruiting

Type 1 DiabetesApproved

Withdrawn

HypoglycemiaApproved

Completed

HyperglycemiaApproved

Completed

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Symlin

AstraZeneca

Approved

1 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes4 trials

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00505882

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06046417·30 enrolled

Pramlintide in Adolescents With Type 1 Diabetes

Completed·UUniversity of Colorado, Denver·N/A·NCT00842075·10 enrolled

Show 1 more trial

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT05199714·12 enrolled

Hyperglycemia2 trials

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Completed·—·Phase 4·NCT01269047·37 enrolled

Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

Completed·LLudwig-Maximilians - University of Munich·N/A·NCT00489645·27 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT04252612

AML1 trial

The Effect of Pramlintide on Meal Time Insulin Bolus

Completed·DDiabetes Care Center·N/A·NCT00460304·12 enrolled

Pediatric1 trial

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

Completed·—·Phase 3·NCT00206297·20 enrolled

6 more indications

Magnetic Resonance Imaging1 trial

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

Unknown status·OOregon Health and Science University·N/A·NCT00691158·10 enrolled

Schizophrenia1 trial

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00690235·33 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Unknown status·—·Phase 3·NCT01137695·40 enrolled

Diabetes Mellitus1 trial

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

Withdrawn·UUniversity of Colorado, Denver·Phase 1/2·NCT01165944

Infusion1 trial

Continuous Subcutaneous Infusion of Pramlintide and Insulin

Completed·—·Phase 4·NCT00291772·13 enrolled

Hypoglycemia1 trial

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Completed·JJoslin Diabetes Center·Phase 4·NCT01841359·22 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 25, 2007

SYMLIN

NDA NDA021332

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for pramlintide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pramlintide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pramlintide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021332). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Symlin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes4 trials

Hyperglycemia2 trials

Cutaneous Squamous Cell Carcinoma1 trial

AML1 trial

Pediatric1 trial

Magnetic Resonance Imaging1 trial

Schizophrenia1 trial

Type 2 Diabetes Mellitus1 trial

Diabetes Mellitus1 trial

Infusion1 trial

Hypoglycemia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News